Drug Patents owned by Seagen
1. List of Tukysa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(1 year, 9 months from now) | |
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(4 years from now) | |
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(9 years from now) | |
| US11504370 | SEAGEN | NA |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic